Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.
P/E ratio for Rani Therapeutics Holdings, Inc. (RANI)
P/E ratio as of 2023: -2.49
According to Rani Therapeutics Holdings, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -2.49. At the end of 2022 the company had a P/E ratio of -2.22.
P/E ratio history for Rani Therapeutics Holdings, Inc. from 2019 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -2.49 |
| 2022 | -2.22 |
| 2021 | -6.07 |
| 2020 | -13.00 |
| 2019 | -8.16 |